The Medical University of Graz in Austria has selected the Indica Labs’ HALO AP digital pathology platform to enhance its diagnostic services.

The platform, alongside Leica Biosystems’ Aperio GT 450 scanners, has been selected by the university’s Diagnostics & Research Institute for Pathology for performance, quality, functionality and usability.

HALO AP comes with the ability to support primary diagnosis with AI-enabled workflows. It simplifies the process for second opinion requests and is capable of managing both research and clinical trials.

The university anticipates digitising approximately 400,000 glass slides annually starting in January 2025.

HALO AP's advanced tools will be crucial in streamlining diagnostic workflows.

 The platform's compatibility with the DICOM file format ensures the accessibility of digitised data for ongoing and future research.

The integration of HALO AP with the existing PAS Xanthos laboratory information system from PROGRAMMIERFABRIK will further optimise the institute's operations.

This integration is a strategic move to enhance the efficiency of diagnostic processes at the university hospital.

The digitisation of tumour boards is another goal for the Medical University of Graz, utilising HALO AP. The platform will also be instrumental in the education of medical students and resident pathologists, due to its capability to create annotated digital training sets.

HALO AP has received CE-IVDR marking for in-vitro diagnostic use in the UK, Europe, and Switzerland.

However, HALO AP is designated for research use only in the US and is not cleared by the US Food and Drug Administration (FDA) for clinical diagnostic use.

In May 2024, Indica Labs secured 510(k) clearance from the FDA for its enterprise digital pathology platform, HALO AP Dx.